JASPAC-01

UMIN000000655 📎

Regimen

Experimental
S-1 (tegafur/gimeracil/oteracil) 80-120 mg/day d1-28 q6w x 4 cycles.
Control
Gemcitabine 1000 mg/m2 weekly x 3 of 4 weeks x 6 cycles.

Population

Resected PDAC (R0/R1), post-surgery within 10 weeks, ECOG PS 0-1, Japanese multicenter (33 hospitals).

Key finding

JASPAC-01 established oral S-1 as the Japanese/East Asian standard adjuvant regimen, nearly doubling 5-year OS vs gemcitabine. The effect size is unprecedented and has not been replicated in Western populations, likely due to CYP2A6 pharmacogenomic differences affecting S-1 metabolism.

Source: PMID 27265347

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.118)